This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
The First 10 Questions for Would-be Searchers
Nieboer, Ian; Carenzo, Mathieu; Davila, AntonioTechnical Note EN-15-EEntrepreneurship, FinanceThis note answers ten of the most common questions asked by people who are relatively new to the search fund model, or have never heard of a search fund before. The content of this note is based on the experience of search funds from around the world, and will help prospective entrepreneurs become familiar with the search fund model and the important questions that should be answered before considering the model more seriously. At the end of each...Starting at €8.20
-
Consideraciones a tener en cuenta en las adqquisiciones empresariales
Nieboer, Ian; Carenzo, Mathieu; Davila, AntonioTechnical Note EN-16Entrepreneurship, Finance, Innovation and ChangeEsta nota técnica sintetiza algunas entrevistas con compradores y financieros empresariales de todo el mundo. Las opiniones y recomendaciones que aparecen a continuación reflejan las diversas experiencias de los profesionales que se dedican a las adquisiciones empresariales, a la vez que pretende resumir las consideraciones que cualquier empresario potencial debe tener presente cuando se embarca en una oportunidad de adquisición empresarial.Starting at €8.20
-
Diez preguntas a tener en cuenta antes de hacer una adquisición emprendedora
Nieboer, Ian; Carenzo, Mathieu; Davila, AntonioTechnical Note EN-15Entrepreneurship, FinanceEsta nota técnica responde a diez de las preguntas más frecuentes que se plantean las personas que nunca han oído hablar del modelo de search fund o aquellas para las que es relativamente nuevo. Su contenido se basa en la experiencia de los search funds en todo el mundo y ayudará a los futuros empresarios a familiarzarse con este modelo y con las respuestas que deben dar a esas diez preguntas antes de plantearse más seriamente crear un search fun...Starting at €8.20
-
GROW: Using Artificial Intelligence to Screen Human Intelligence
Bernstein, Ethan S.; McKinnon, Paul D.; Yarabe, PaulCase HBS-418020-ELeadership and People ManagementOver 10% of all 2017 university graduates in Japan used GROW, an artificial intelligence platform and mobile app developed by Tokyo-based people analytics startup IGS, to recruit for a job. This case puts participants in the shoes of IGS founder and CEO Masahiro Fukuhara, a first-time entrepreneur, as he considers the varied ways the "big data" he is collecting is being used--and whether some uses promised more meaningful (or less potentially mis...Starting at €8.20
-
U.S. Universities and Technology Transfer
Hamermesh, Richard G.; Lerner, Josh; Andrews, PhillipCase HBS-812016-EEntrepreneurshipTechnology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology tra...Starting at €8.20
-
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
Hamermesh, Richard G.; Kucherlapati, Raju; Gordon, RachelCase HBS-810066-EEntrepreneurshipIn May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had received approval several years prior. Moreover, Vectibix had also received Food and Drug Administration approval in 2006. During additional trials, Amgen has learned that the Vectibix...Starting at €8.20
-
Syndexa and Technology Transfer at Harvard University
Hamermesh, Richard G.; Kiron, DavidCase HBS-808073-EGokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the head of Harvard's Office of Technology Development (OTD) is eager to improve Harvard's record in commercializing science. Describes the negotiations between Hotamisligil, OTD, the ne...Starting at €8.20
-
Lyric Dinner Theater (B) (Spanish version)
Hamermesh, Richard G.; Sharpe, James M.Case HBS-815S17EntrepreneurshipSuplementos el caso (A). Rivka Belzer refleja en los resultados y las medidas adoptadas durante los 12 meses siguientes a su primer 6 meses en el trabajo. Suplementos el caso (A). Rivka Belzer tomó un trabajo en su empresa familiar y trabajó diligentemente durante los primeros 6 meses para convertir el negocio alrededor. Este caso suplementario esboza una serie de decisiones que hizo después de los 6 meses y reporta los resultados financieros un ...Starting at €5.74
-
Sugar Bowl (Spanish version)
Hamermesh, Richard G.; Zalosh, AlisaCase HBS-917S11StrategyShelby Givens, a recent business school graduate, returned home to Raleigh, North Carolina to help rescue her family's ailing and outdated bowling alley, Westlake Lanes. Although she cut costs and addressed inefficiencies, moving the business from near-bankruptcy to profitability in nine months, market conditions threatened the long-term viability of the business. Givens then sold her family on a new, more youth-oriented concept, an urban lounge ...Starting at €8.20
-
Note on Managing the Growing Venture (Spanish version)
Hamermesh, Richard G.; Heskett, James L.; Roberts, Michael J.Case HBS-808S03EntrepreneurshipFocuses on the strategic and organizational challenges that confront growing enterprises and the entrepreneurs who lead them. Provides an overview of how a new venture needs to change as it passes from the initial start-up to the growth phase. Explores how a venture's leadership, strategy, and execution need to evolve to deal with rapid growth. A rewritten version of an earlier note.Starting at €8.20